ACXP Key Statistics, Chart & Performance
The current stock price of ACXP is 2.92 USD. In the past month the price decreased by -31.13%. In the past year, price decreased by -81.94%.
ACXP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About ACXP
Company Profile
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
Company Info
ACURX PHARMACEUTICALS INC
259 Liberty Avenue
Staten Island NEW YORK US
CEO: David P. Luci
Employees: 4
Phone: 19175331469
ACURX PHARMACEUTICALS INC / ACXP FAQ
What does ACURX PHARMACEUTICALS INC do?
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
What is the current price of ACXP stock?
The current stock price of ACXP is 2.92 USD. The price increased by 0.34% in the last trading session.
Does ACURX PHARMACEUTICALS INC pay dividends?
ACXP does not pay a dividend.
How is the ChartMill rating for ACURX PHARMACEUTICALS INC?
ACXP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ACXP stock?
ACURX PHARMACEUTICALS INC (ACXP) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of ACXP stock?
ACURX PHARMACEUTICALS INC (ACXP) has a market capitalization of 6.10M USD. This makes ACXP a Nano Cap stock.
ACXP Technical Analysis
ACXP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ACXP. The financial health of ACXP is average, but there are quite some concerns on its profitability.
ACXP Financial Highlights
Over the last trailing twelve months ACXP reported a non-GAAP Earnings per Share(EPS) of -8.52. The EPS increased by 60.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -150.2% | ||
| ROE | -252.13% | ||
| Debt/Equity | 0 |
ACXP Forecast & Estimates
9 analysts have analysed ACXP and the average price target is 62.93 USD. This implies a price increase of 2055.27% is expected in the next year compared to the current price of 2.92.